HIMS climbs 6% despite FTC privacy lawsuit and guidance miss
24/7 Wall St. · · AI-summarised by FinFlash
Hims & Hers shares rose 6% to about $20.34, partly recovering a 17% plunge on Tuesday, even after Reuters reported that five US states joined the Federal Trade Commission's lawsuit over the company's privacy practices, with the expanded case also covering billing. Third-quarter revenue grew 48.6% to $890.37 million, slightly short of forecasts, and fourth-quarter guidance of $875 million to $895 million trailed the $954.58 million consensus.
So What?
Legal and guidance overhangs keep volatility high for telehealth names. Novo Nordisk's planned US list-price cuts for Wegovy and Ozempic from January add pricing pressure.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.